Issued 2026-08-13 at $332.86 · now $328.34 (2026-08-13, −1.4% since)
Based on its own history, a month from the 2026-08-13 close, KRYS has typically landed between $278.33 and $406.11 — a range of −16.4% to +22.0% from the issuance price $332.86.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
2,214 overlapping 1 month windows · 2017-09-20 – 2026-07-15 · basis climatology · forecast (batch). Probability up 53.8% (90% CI 51.6–56.0%, ≈1,400 obs).
The cone is anchored at the 2026-08-13 issuance close ($332.86) — the price the forecast resolves against on 2026-09-11, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where KRYS has typically landed a month from the 2026-08-13 close of $332.86 — the range is history, not a prediction.
- now $328.34 (-1.4%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $340.03 (+2.2%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $313–$367.05
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $278.33–$406.11
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2020-02-18 | −43.7% | −43.7% | +0.8% |
| 2020-02-13 | −40.7% | −40.7% | +0.0% |
| 2020-02-11 | −39.3% | −39.3% | +3.5% |
| 3 best | |||
| 2021-11-26 | +77.7% | +0.0% | +102.3% |
| 2019-06-20 | +77.4% | +0.0% | +77.4% |
| 2019-06-14 | +75.3% | +0.0% | +75.3% |
2,214 overlapping windows · 2017-09-20 – 2026-08-13 · not cherry-picked
Pending catalysts
- December 2026 — Trial primary completion: Phase 3 primary completion: A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa (source, as of 2026-08-14)
- December 2026 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis (source, as of 2026-08-14)
- February 2027 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs (source, as of 2026-08-14)
- July 2027 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~9 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Company insiders iOpen-market share purchases and sales by the company's own officers and directors, by filing date.
Last 90 days · as of 2026-08-13 · point-in-time by filing date
No insider transactions on record in the last 90 days.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. Full terms.